Any lower and it would be getting a bit silly, we have a revenue generating bio tech in a hot space with enough cash runway for 12months +, no debt, regulatory approvals (BIOPLATE U.S. aside) , very tight register and strong management.
It's a BUY
Ann: Appendix 4E Preliminary Final Report, page-14
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
